Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96LU5
UPID:
IMP1L_HUMAN
Alternative names:
IMP1-like protein
Alternative UPACC:
Q96LU5; D3DQZ7; Q96SH9
Background:
Mitochondrial inner membrane protease subunit 1, also known as IMP1-like protein, plays a crucial role in mitochondrial function. It catalyzes the removal of transit peptides during the targeting of proteins from the mitochondrial matrix across the inner membrane into the inter-membrane space, processing the nuclear-encoded protein DIABLO among others.
Therapeutic significance:
Understanding the role of Mitochondrial inner membrane protease subunit 1 could open doors to potential therapeutic strategies.